BioSpace News Archive

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) announces the voting results from the Annual General and Special Meeting of Shareholders (the “Meeting”) which was held on December 6, 2023.

FibroBiologics, Inc. today announced that it will hold an Investor Day on December 14, 2023.

Kedrion Biopharma announces the execution of a binding memorandum of understanding with Kamada Ltd., an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.

GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Esophagus (PATENT-E) study.

BioGenCell has announced the inauguration of the fifth Phase II cell-therapy-based clinical trial site for Chronic Limb-Threatening Ischemia in the United States at the University of Maryland Medical Center.

Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced that CEO Greg Kunst has won one of the Healthcare Leadership awards from the Puget Sound Business Journal.

MBrace Therapeutics, Inc. (“MBrace”) today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

AOP Orphan Pharmaceuticals GmbH announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera 1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients.

ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Alternative Therapies, demonstrating that plasma NLRP3 inflammasomes and their resulting proinflammatory cytokines are significantly elevated in early-stage DKD and that levels progressively increase as kidney function worsens.